Osteoporosis Drugs Market, Size, Share, Global Forecast 2023-2030, Industry Trends, Growth, Impact of Inflation, Opportunity Company Analysis

Osteoporosis Drug Market will reach US$ 12.82 Billion in 2022

Osteoporosis drugs market is projected to value US$ 17.52 Billion by the year 2030, according to the report. Osteoporosis persists undetected and untreated in at-risk groups despite the availability of several prescription drugs, acknowledged risk assessment techniques, and diagnostic criteria. The field of clinical research on osteoporosis has a wonderful chance to help patients with improved and more affordable medicines. One in three women and one in five men throughout the world are at risk of osteoporotic fractures. This ailment affects more than 200 million individuals globally. In the United States and Europe, osteoporosis affects about 30% of postmenopausal women. Unexpectedly, the rates of treatment start remain unexpectedly low, ranging from 5% to 30%, despite the availability of several authorized drugs for osteoporosis and even after the incidence of verified osteoporotic fractures.

A decline in bone mass and density is a symptom of osteoporosis. The bones get weaker as a result and break more easily. The aging population, rising awareness, improved treatment options, and cost-effectiveness drive the need for osteoporosis drugs in response to the increased risk of osteoporosis. The availability of effective drugs makes treatment more accessible, and their cost-effectiveness compared to fracture expenses highlights their importance in managing the condition. Asian and white women are the most susceptible. Surprisingly, because there is no specific alternative to treating osteoporosis (such as surgery), the Osteoporosis Drugs industry is a necessary component of osteoporosis treatment everywhere.

Osteoporosis drugs market is anticipated to grow at a CAGR of 3.98% during 2022-2030

The availability of various effective osteoporosis drugs has improved accessibility to treatment, moving beyond the limitations of hormone replacement therapy (HRT), which is no longer recommended due to associated cancer risks. The development of new drugs like bisphosphonates and teriparatide has enhanced treatment effectiveness and safety. Osteoporosis drugs are also cost-effective compared to the expenses associated with fractures, which can be financially burdensome.

There is a growing focus on innovative drug delivery systems, aiming to enhance efficacy, safety, and patient convenience. Extensive research and development efforts are underway in the osteoporosis drug market, exploring new medications, delivery systems, and diagnostic and treatment approaches. However, cost, side effects, adherence, effectiveness variation, and lack of awareness pose barriers to Osteoporosis Drugs Market; ongoing research offers hope for improved drugs. As a result, the global osteoporosis drug market will reach US$ 12.82 Billion in 2022.

Global market for generic osteoporosis drugs is expected to expand due to patent expiration, rising awareness, and supportive government policies
By Type, the global osteoporosis drug market is divided into Branded and Generic. With the expiration of patents on branded drugs, the availability of generic versions is on the rise, resulting in substantial price reductions. Increased awareness of cost-effective generic drugs among patients and healthcare professionals drives their growing popularity in Osteoporosis Drugs Market due to lower prices and the absence of research and patent costs. Government policies that encourage the use of generics, such as requirements in public hospitals and clinics, further drive down prices and increase demand.

Branded drugs, protected by patents, enjoy advantages over generic drugs due to marketing, brand loyalty, and government regulations. Branded drugs are heavily promoted, increasing awareness and influencing prescriptions. Patients may prefer familiar branded drugs, even if generics are available. Some countries have regulations limiting generic drug availability. Despite higher prices, branded drugs may offer unique benefits. Consultation with a doctor is essential when deciding between branded and generic drugs.

Rank Ligand Inhibitors (RANKL) are projected to have a significant market share in the global osteoporosis market

Bisphosphonates, Selective Estrogen Inhibitors Modulator (SERM), Parathyroid Hormone Therapy, Calcitonin, Rank Ligand Inhibitors, and Others are the drug classes present in the global osteoporosis drug market. RANKL inhibitors, like denosumab (Prolia), effectively reduce fracture risk in osteoporosis. Though generally safe, RANKL inhibitors may have mild side effects such as fatigue, headaches, and back pain, as well as rare but serious side effects like osteonecrosis of the jaw (ONJ). Patent protection and marketing efforts give RANKL inhibitors an advantage over other osteoporosis drugs, and brand loyalty may influence patient preference.

Bisphosphonates, such as alendronate (Fosamax), are effective in reducing the risk of fractures in people with osteoporosis. A study published in The New England Journal of Medicine found that bisphosphonates decreased the risk of hip fractures by 50% in women with osteoporosis. The patent protection and marketing efforts of bisphosphonate manufacturers contribute to their higher market shares compared to other osteoporosis drugs, despite the availability of generic equivalents.

Oral administration is the preferred and most convenient route for most people due to its ease and avoidance of injections or infusions

Oral, Injectable, and Others are the routes of administration present in the global osteoporosis market. Oral drugs are cost-effective and safe, but they may cause mild side effects, including rare serious effects like osteonecrosis of the jaw. In terms of effectiveness, oral medications have proven to be successful in treating osteoporosis, as demonstrated by alendronate's (Fosamax) ability to reduce the risk of hip fractures by 50%. Patients commonly prefer oral drugs due to their convenience and the avoidance of injections or infusions, as indicated by studies focusing on patient preferences.

Injectable drugs like denosumab (Prolia) are effective and provide immediate effects for treating osteoporosis. Though generally safe, they can cause mild side effects and rare serious effects like osteonecrosis of the jaw (ONJ). Patent protection ensures exclusivity and higher prices. Injectable drug manufacturers invest in marketing, influencing prescriptions. Brand loyalty drives Osteoporosis Drugs Market, despite other options.

Online pharmacies are the fastest-growing segment of the global osteoporosis market due to their convenience, affordability, variety, privacy, and 24/7 availability.

By Distribution Channel, the global osteoporosis drugs market is segmented into Hospital pharmacies, Retail pharmacies, and online pharmacies. Hospital pharmacies have advantages in administering injectable osteoporosis drugs due to their expertise, patient support, and cost-effectiveness. Complex dosing regimens are better managed by hospital pharmacists, who can educate and monitor patients. They offer convenience and lower costs thanks to their larger buying power and government regulations.

Although hospital pharmacies currently dominate the Osteoporosis Drugs Market, patients have a convenient and cost-effective alternative for ordering osteoporosis medications through online pharmacies. By taking advantage of reduced costs and a wide range of brand-name and generic medications, patients can find affordable solutions. Furthermore, the privacy policies and round-the-clock accessibility of internet pharmacies have enhanced the overall experience for patients.

United States has leadership in the global osteoporosis drug market

The United States, Canada, France, Germany, Italy, Spain, the United Kingdom, Belgium, the Netherlands, China, Japan, India, Australia, South Korea, Thailand, Malaysia, Indonesia, New Zealand, Brazil, Mexico, Argentina, South Africa, Saudi Arabia, Turkey, the UAE, and Rest of World are the countries constituting the global osteoporosis drug market. In the United States, osteoporosis is a significant problem due to the large aging population. In addition to the roughly 10 million people who already suffer from the illness, an additional 44 million Americans have low bone mass.

Osteoporosis is well understood in the country, which increases the need for treatments and pharmaceuticals. The United States, which has a robust research and development sector, has seen major investments in Osteoporosis Drugs Market research from top pharmaceutical companies. The population high disposable earnings enable them to be able to afford osteoporosis drugs and therapies, unlike other countries where reliance on government programs or charitable organizations may be necessary. The majority of health insurance plans in the United States include osteoporosis, ensuring greater access to essential care.

Key Players

Companies participating in the global osteoporosis drugs market include Eli Lilly and Company, Pfizer Inc., F. Hoffmann-La Roche, Teva Pharmaceutical Industries Ltd., GlaxoSmithKline plc, Novartis International AG, Merck & Co. Inc., and Amgen Inc.

In August 2021, The Medicine Controller General of India (DCGI) granted Enzene Biosciences Ltd. marketing authorization (MA) for denosumab, a biosimilar medicine used to treat osteoporosis in adults.

This latest report “Global Osteoporosis Drugs Market, Type (Branded and Generic), Drug Class (Bisphosphonates, Selective Estrogen Inhibitors Modulator (SERM), Parathyroid Hormone Therapy, Calcitonin, Rank Ligand Inhibitors, and Others), Route of Administration (Oral, Injectable, and Others), Distribution Channel (Hospital pharmacies, Retail pharmacies, and Online pharmacies), Countries (United States, Canada, France, Germany, Italy, Spain, United Kingdom, Belgium, Netherlands, China, Japan, India, Australia, South Korea, Thailand, Malaysia, Indonesia, New Zealand, Brazil, Mexico, Argentina, South Africa, Saudi Arabia, Turkey, UAE, and ROW), Companies (Eli Lilly and Company, Pfizer Inc., F. Hoffmann-La Roche, Teva Pharmaceutical Industries Ltd., GlaxoSmithKline plc., Novartis International AG, Merck & Co. Inc., and Amgen Inc.)” provides a detailed analysis of Global Osteoporosis Drugs Market.

Types - Global Osteoporosis Drugs Market has been covered from 2 viewpoints:

1. Branded
2. Generic

Drug Class - Global Osteoporosis Drugs Market has been covered from 6 viewpoints:

1. Bisphosphonates
2. Selective Estrogen Inhibitors Modulator (SERM)
3. Parathyroid Hormone Therapy
4. Calcitonin
5. Rank Ligand Inhibitors
6. Others

Route of Administration - Global Osteoporosis Drugs Market has been covered from 3 viewpoints:

1. Oral
2. Injectable
3. Others

Distribution Channels - Global Osteoporosis Drugs Market has been covered from 3 viewpoints:

1. Hospital pharmacies
2. Retail pharmacies
3. Online pharmacies

Countries - Global Osteoporosis Drugs Market has been covered from 26 viewpoints:

1North America

1.1 United States
1.2 Canada

2Europe

2.1 France
2.2 Germany
2.3 Italy
2.4 Spain
2.5 United Kingdom
2.6 Belgium
2.7 Netherland

3Asia Pacific

3.1 China
3.2 Japan
3.3 India
3.4 Australia
3.5 South Korea
3.6 Thailand
3.7 Malaysia
3.8 Indonesia
3.9 New Zealand

4Latin America

4.1 Brazil
4.2 Mexico
4.3 Argentina

5Middle East & Africa

5.1 South Africa
5.2 Saudi Arabia
5.3 Turkey
5.4 UAE

6Rest of the World

Company Insights:

• Overview
• Recent Development
• Financial Insight

Company Analysis:

1. Eli Lilly and Company
2. Pfizer Inc.
3. F. Hoffmann-La Roche
4. Teva Pharmaceutical Industries Ltd.
5. GlaxoSmithKline plc.
6. Novartis International AG
7. Merck & Co. Inc.
8. Amgen Inc.